{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:18:35Z","timestamp":1792844315520,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12024-1","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:25:55Z","timestamp":1779863155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Time-resolved Hippo\u2013YAP transcript and microRNA responses to imatinib in K562 chronic myeloid leukemia cells with exploratory analysis of CD34\u207a progenitor transcriptomes"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5349-4997","authenticated-orcid":false,"given":"Soroush","family":"Akbari-Ardabili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-2805","authenticated-orcid":false,"given":"Safiyeh","family":"Aghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-4389","authenticated-orcid":false,"given":"Mehdi","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"12024_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/NRC1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183. https:\/\/doi.org\/10.1038\/NRC1567","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"12024_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030958","volume":"15","author":"A Wu","year":"2023","unstructured":"Wu A, Turner KA, Woolfson A, Jiang X (2023) The hedgehog pathway as a therapeutic target in chronic myeloid leukemia. Pharmaceutics 15(3):15:958. https:\/\/doi.org\/10.3390\/pharmaceutics15030958","journal-title":"Pharmaceutics"},{"key":"12024_CR3","doi-asserted-by":"publisher","unstructured":"Helgason V, Copland M, Krause Rahul Kumar DS (2021) Faculty Opinions Recent advances in understanding chronic myeloid leukemia: where do we stand? Fac Rev 10. https:\/\/doi.org\/10.12703\/r\/10-35","DOI":"10.12703\/r\/10-35"},{"issue":"2","key":"12024_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020659","volume":"22","author":"Y Yung","year":"2021","unstructured":"Yung Y, Lee E, Chu HT et al (2021) Targeting abnormal hematopoietic stem cells in chronic myeloid leukemia and Philadelphia Chromosome-Negative classical myeloproliferative neoplasms. Int J Mol Sci 22(2):659. https:\/\/doi.org\/10.3390\/ijms22020659","journal-title":"Int J Mol Sci"},{"key":"12024_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/BLOODADVANCES.2018020503","volume":"3","author":"A Yokota","year":"2019","unstructured":"Yokota A, Hirai H, Sato R et al (2019) C\/EBP\u03b2 is a critical mediator of IFN-\u03b1\u2013induced exhaustion of chronic myeloid leukemia stem cells. Blood Adv 3:476\u2013488. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2018020503","journal-title":"Blood Adv"},{"key":"12024_CR6","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S382090","author":"I Rinaldi","year":"2023","unstructured":"Rinaldi I, Winston K (2023) Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. J Blood Med. https:\/\/doi.org\/10.2147\/JBM.S382090","journal-title":"J Blood Med"},{"key":"12024_CR7","doi-asserted-by":"publisher","DOI":"10.5772\/INTECHOPEN.97528","author":"E Bracco","year":"2021","unstructured":"Bracco E, Ali MS, Magnati S et al (2021) The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL. Adv Precis Med Oncol. https:\/\/doi.org\/10.5772\/INTECHOPEN.97528","journal-title":"Adv Precis Med Oncol"},{"key":"12024_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14656566.2017.1421633","volume":"19","author":"E Atallah","year":"2018","unstructured":"Atallah E, Ritchie E (2018) Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? Expert Opin Pharmacother 19:79\u201381. https:\/\/doi.org\/10.1080\/14656566.2017.1421633","journal-title":"Expert Opin Pharmacother"},{"key":"12024_CR9","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/BCP.13637","volume":"84","author":"AE E\u015fkazan","year":"2018","unstructured":"E\u015fkazan AE (2018) Evolving treatment strategies in CML \u2013 moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? Br J Clin Pharmacol 84:1635\u20131638. https:\/\/doi.org\/10.1111\/BCP.13637","journal-title":"Br J Clin Pharmacol"},{"key":"12024_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/ASHEDUCATION-2018.1.161","volume":"2018","author":"S Claudiani","year":"2018","unstructured":"Claudiani S, Apperley JF (2018) The argument for using imatinib in CML. Hematology 2018:161\u2013167. https:\/\/doi.org\/10.1182\/ASHEDUCATION-2018.1.161","journal-title":"Hematology"},{"key":"12024_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.862504","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhu M, Li M et al (2022) Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1. Front Pharmacol 13:862504. https:\/\/doi.org\/10.3389\/FPHAR.2022.862504","journal-title":"Front Pharmacol"},{"key":"12024_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913\u2013923. https:\/\/doi.org\/10.7326\/0003-4819-145-12-200612190-00008","journal-title":"Ann Intern Med"},{"key":"12024_CR13","doi-asserted-by":"publisher","DOI":"10.3760\/CMA.J.ISSN.1673-419X.2019.04.010","author":"X Jia","year":"2019","unstructured":"Jia X, Cai Z (2019) Research progress in treatment of chronic myeloid leukemia patients with imatinib resistance. Int J Blood Transfus Hematol. https:\/\/doi.org\/10.3760\/CMA.J.ISSN.1673-419X.2019.04.010","journal-title":"Int J Blood Transfus Hematol"},{"key":"12024_CR14","doi-asserted-by":"publisher","first-page":"vi39","DOI":"10.1093\/annonc\/mdz345","volume":"30","author":"D Rea","year":"2019","unstructured":"Rea D (2019) New therapeutic strategies for overcoming resistance and disease persistence in CML. 2019 Japanese Soc Med Oncol Annu Meet 18\u00e2\u20ac20 July 2019. Kyoto Japan 30:vi39. https:\/\/doi.org\/10.1093\/annonc\/mdz345","journal-title":"Kyoto Japan"},{"key":"12024_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S et al (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers 13:13:4820. https:\/\/doi.org\/10.3390\/CANCERS13194820","journal-title":"Cancers"},{"key":"12024_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.15252\/EMBR.201438638","volume":"15","author":"J Mo","year":"2014","unstructured":"Mo J, Park HW, Guan K (2014) The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 15:642\u2013656. https:\/\/doi.org\/10.15252\/EMBR.201438638","journal-title":"EMBO Rep"},{"key":"12024_CR17","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1073\/PNAS.1807325115","volume":"115","author":"J Mach","year":"2018","unstructured":"Mach J, Atkins M, Gajewski KM et al (2018) Modulation of the Hippo pathway and organ growth by RNA processing proteins. Proc Natl Acad Sci U S A 115:10684\u201310689. https:\/\/doi.org\/10.1073\/PNAS.1807325115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12024_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/ANNUREV-BIOCHEM-013118-111829\/CITE\/REFWORKS","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan KL (2019) The Hippo pathway: biology and pathophysiology. Annu Rev Biochem 88:577\u2013604. https:\/\/doi.org\/10.1146\/ANNUREV-BIOCHEM-013118-111829\/CITE\/REFWORKS","journal-title":"Annu Rev Biochem"},{"key":"12024_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/ANNUREV-GENET-120417-031621\/CITE\/REFWORKS","volume":"52","author":"JR Misra","year":"2018","unstructured":"Misra JR, Irvine KD (2018) The Hippo signaling network and its biological functions. Annu Rev Genet 52:65\u201387. https:\/\/doi.org\/10.1146\/ANNUREV-GENET-120417-031621\/CITE\/REFWORKS","journal-title":"Annu Rev Genet"},{"key":"12024_CR20","doi-asserted-by":"publisher","first-page":"IA27","DOI":"10.1158\/1557-3125.HIPPO19-IA27","volume":"18","author":"Y Lu","year":"2020","unstructured":"Lu Y, Wu T, Zhu Q et al (2020) Abstract IA27: regulation of Hippo and TAZ signaling in breast cancer. Mol Cancer Res 18:IA27\u2013IA27. https:\/\/doi.org\/10.1158\/1557-3125.HIPPO19-IA27","journal-title":"Mol Cancer Res"},{"key":"12024_CR21","doi-asserted-by":"publisher","DOI":"10.1096\/FASEBJ.2022.36.S1.R2422","author":"Y Song","year":"2022","unstructured":"Song Y, Gill MK, Song S, Attisano L (2022) Identification of NUAK1\/2 regulators in the hippo signaling pathway. FASEB J. https:\/\/doi.org\/10.1096\/FASEBJ.2022.36.S1.R2422","journal-title":"FASEB J"},{"key":"12024_CR22","unstructured":"Heidaryarash E (2018) Identification and Characterization of Novel. Upstream Regulators of the Hippo Signalling Pathway"},{"key":"12024_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/J.DEVCEL.2019.06.003","volume":"50","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Pan D (2019) The Hippo Signaling Pathway in Development and Disease. Dev Cell 50:264. https:\/\/doi.org\/10.1016\/J.DEVCEL.2019.06.003","journal-title":"Dev Cell"},{"key":"12024_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/FEBS.13985","volume":"284","author":"N Li","year":"2017","unstructured":"Li N, Xie C, Lu N (2017) Crosstalk between hippo signalling and miRNAs in tumour progression. FEBS J 284:1045\u20131055. https:\/\/doi.org\/10.1111\/FEBS.13985","journal-title":"FEBS J"},{"key":"12024_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153241","author":"RV Astamal","year":"2020","unstructured":"Astamal RV, Maghoul A, Taefehshokr S et al (2020) Regulatory role of microRNAs in cancer through Hippo signaling pathway. Pathol Res Pract. https:\/\/doi.org\/10.1016\/j.prp.2020.153241","journal-title":"Pathol Res Pract"},{"issue":"8","key":"12024_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5483\/BMBRep.2023-0094","volume":"56","author":"I Kim","year":"2023","unstructured":"Kim I, Park T, Noh JY, Kim W (2023) Emerging role of Hippo pathway in the regulation of hematopoiesis. BMB Rep 56(8):417\u2013425. https:\/\/doi.org\/10.5483\/BMBRep.2023-0094","journal-title":"BMB Rep"},{"key":"12024_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M (2022) The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther 7:376. https:\/\/doi.org\/10.1038\/s41392-022-01191-9","journal-title":"Signal Transduct Target Ther"},{"key":"12024_CR28","doi-asserted-by":"publisher","DOI":"10.2306\/scienceasia1513-1874.2025.060","volume":"51","author":"W Saisaard","year":"2025","unstructured":"Saisaard W, Klaihmon P, Thanasupharom K, Lorthongpanich C, Luanpitpong S, Phannasil P, Owattanapanich W, Issaragrisil S (2025) Hippo\/STK4 is downregulated in imatinib-resistant chronic myeloid leukemia and its restoration enhances apoptosis. ScienceAsia 51:2025060. https:\/\/doi.org\/10.2306\/scienceasia1513-1874.2025.060","journal-title":"ScienceAsia"},{"key":"12024_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u2206\u2206CT method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"12024_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0115293","volume":"9","author":"LH Yang","year":"2014","unstructured":"Yang LH, Wang SL, Tang LL et al (2014) Universal stem-loop primer method for screening and quantification of MicroRNA. PLoS One 9:e115293. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0115293","journal-title":"PLoS One"},{"issue":"3","key":"12024_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12032-018-1079-6","volume":"35","author":"APZC Marsola","year":"2018","unstructured":"Marsola APZC, Sim\u00f5es BP, Palma LC et al (2018) Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia. Med Oncol 35(3):1\u201310. https:\/\/doi.org\/10.1007\/S12032-018-1079-6","journal-title":"Med Oncol"},{"key":"12024_CR32","doi-asserted-by":"publisher","first-page":"24273","DOI":"10.1074\/jbc.M002094200","volume":"275","author":"M Sattler","year":"2000","unstructured":"Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al (2000) The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275:24273\u201324278. https:\/\/doi.org\/10.1074\/jbc.M002094200","journal-title":"J Biol Chem"},{"key":"12024_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/biom11040610","volume":"11","author":"S G\u0142owacki","year":"2021","unstructured":"G\u0142owacki S, Synowiec E, Toma M, \u015aliwi\u0144ski T (2021) Relationship between oxidative stress and imatinib resistance in model chronic myeloid leukemia cells. Biomolecules 11:610. https:\/\/doi.org\/10.3390\/biom11040610","journal-title":"Biomolecules"},{"key":"12024_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11623-6","volume":"23","author":"L H\u00e4selbarth","year":"2023","unstructured":"H\u00e4selbarth L, Zhang B, Hader C et al (2023) Synergistic lethality in chronic myeloid leukemia \u2013 targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment. BMC Cancer 23:1210. https:\/\/doi.org\/10.1186\/s12885-023-11623-6","journal-title":"BMC Cancer"},{"key":"12024_CR35","first-page":"1347","volume":"11","author":"S Gao","year":"2018","unstructured":"Gao S, Yang D, Huang W et al (2018) miR-135a-5p affects adipogenic differentiation of human adipose-derived mesenchymal stem cellsby promoting the Hippo signaling pathway. Int J Clin Exp Pathol 11:1347","journal-title":"Int J Clin Exp Pathol"},{"key":"12024_CR36","doi-asserted-by":"crossref","unstructured":"Sun Z, Zhang Q, Yuan W et al (2020) MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo\/YAP1\/HIF1A axis. 39:1\u201316","DOI":"10.1186\/s13046-020-01705-9"},{"key":"12024_CR37","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.19487","author":"ZQ Sun","year":"2017","unstructured":"Sun ZQ, Shi K, Zhou QB et al (2017) MiR-590-3p promotes proliferation and metastasis of colorectal cancer via Hippo pathway. Oncotarget. https:\/\/doi.org\/10.18632\/ONCOTARGET.19487","journal-title":"Oncotarget"},{"key":"12024_CR38","doi-asserted-by":"publisher","first-page":"E24618","DOI":"10.1097\/MD.0000000000024618","volume":"100","author":"CL Qi","year":"2021","unstructured":"Qi CL, Sheng JF, Huang ML et al (2021) Integrated analysis of deregulation microRNA expression in head and neck squamous cell carcinoma. Med (United States) 100:E24618. https:\/\/doi.org\/10.1097\/MD.0000000000024618","journal-title":"Med (United States)"},{"key":"12024_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-022-09396-5","volume":"221 22","author":"A Mohd Yacob","year":"2022","unstructured":"Mohd Yacob A, Muhamad NA, Chang KM et al (2022) Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response. BMC Cancer 2022 221 22:1\u201315. https:\/\/doi.org\/10.1186\/S12885-022-09396-5","journal-title":"BMC Cancer 2022"},{"issue":"20","key":"12024_CR40","doi-asserted-by":"publisher","first-page":"e70901","DOI":"10.1111\/jcmm.70901","volume":"29","author":"S Mutti","year":"2025","unstructured":"Mutti S, Cavalleri A, Federici S et al (2025) Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles. J Cell Mol Med 29(20):e70901. https:\/\/doi.org\/10.1111\/jcmm.70901","journal-title":"J Cell Mol Med"},{"issue":"5","key":"12024_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cbin.70007","volume":"49","author":"A Cavalleri","year":"2025","unstructured":"Cavalleri A, Xhahysa B, Mutti S et al (2025) Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent. Cell Biol Int 49(5):570. https:\/\/doi.org\/10.1002\/cbin.70007","journal-title":"Cell Biol Int"},{"issue":"6","key":"12024_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood.2022018196","volume":"142","author":"S Qiu","year":"2023","unstructured":"Qiu S, Sheth V, Yan C et al (2023) Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells. Blood 142(6):574\u2013588. https:\/\/doi.org\/10.1182\/blood.2022018196","journal-title":"Blood"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12024-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12024-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12024-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T01:02:10Z","timestamp":1783818130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12024-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12024"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12024-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Graphical abstract has been added","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve human participants or live vertebrate animals. The in vitro experiments were performed using an established human cell line (K562). The analysis of publicly available microarray datasets (GSE12211 and GSE14671) was conducted in accordance with the data usage policies of the Gene Expression Omnibus (GEO), and no additional ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) to assist with language editing and text organization. All content was critically reviewed and edited by the authors, who take full responsibility for the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted"}}],"article-number":"835"}}